Arch Biopartners Expands Phase II Trial for LSALT Peptide in Cardiac Surgery Kidney Injury

Event summary

  • St. Michael’s Hospital begins dosing patients in Arch Biopartners’ Phase II trial for LSALT peptide, targeting cardiac surgery-associated acute kidney injury (CS-AKI).
  • Three Canadian sites are actively recruiting patients, with additional U.S. and Ontario sites under consideration.
  • No adverse events related to LSALT peptide have been reported, and the trial remains on track with 240 patient recruitment target.
  • Arch is also advancing the PONTiAK Phase II trial for cilastatin, aiming to prevent AKI from nephrotoxic pharmaceuticals.

The big picture

Arch Biopartners is advancing its lead drug candidate, LSALT peptide, in a Phase II trial targeting a significant unmet medical need in cardiac surgery-associated acute kidney injury. The expansion of trial sites into the U.S. and additional Canadian locations underscores the company’s strategic push to validate its therapeutic approach and capture broader market attention. With no approved pharmacologic therapies for CS-AKI, Arch’s progress could position LSALT peptide as a first-in-class treatment, addressing a condition that affects up to 30% of on-pump cardiac surgery patients.

What we're watching

Trial Expansion
Whether Arch can successfully integrate new U.S. and Canadian sites to accelerate patient recruitment and broaden clinical awareness of LSALT peptide.
Regulatory Progress
The pace at which Arch advances discussions with additional cardiac surgery centers and secures clinical trial agreements.
Therapeutic Validation
How preliminary data from the Phase II trial will influence the perceived efficacy and safety of LSALT peptide in preventing CS-AKI.